Clinical trials
Newly Diagnosed clinical trials
Below are recruiting newly diagnosed clinical trials, each written for real people, not researchers. We’re tracking 393 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Birmingham, AlabamaAges 18 years+ - NCT06906653Enrolling by invitation
Proactive care for newly diagnosed type 2 diabetes
This trial tests a new, proactive approach to help people newly diagnosed with type 2 diabetes manage their condition through better initial care and support. If you’re a Kaiser Permanente Northern California member, you may get extra resources and guidance right from the start.
Pleasanton, CaliforniaAges 18–74 - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT06882057RecruitingPhase 2/Phase 3
Treatment for newly diagnosed low-risk pediatric B-ALL
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
Hefei, AnhuiAges 1–18 - NCT06332573Recruiting
Onco-sexology support for newly diagnosed cancer patients
This trial tests whether talking with a specialist about sexual well-being can improve your quality of life after a new cancer diagnosis. It's for anyone aged 18 or older, including those receiving palliative care.
MarseilleAges 18 years+ - NCT06852222RecruitingPhase 3
Study of bleximenib, venetoclax, and azacitidine for newly diagnosed AML
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Birmingham, AlabamaAges 18 years+ - NCT06855706Recruiting
Personalized physical activity program for ovarian and endometrial cancers
This study tests whether a personalized, automated physical activity program (using a Fitbit and continuous glucose monitor) can improve immune function and health outcomes in people with advanced ovarian, primary peritoneal, fallopian tube, or newly diagnosed endometrial cancer. You'll wear an activity tracker, answer questionnaires, and provide blood and stool samples at Roswell Park.
Buffalo, New YorkAges 18 years+ - NCT06857071Recruiting
Using social networks to find undiagnosed HIV cases
This study tests whether asking people with a new HIV diagnosis to invite their friends and contacts for testing can find more undiagnosed cases and reduce stigma. If you or someone you know was recently diagnosed with HIV in the Msunduzi area, this could help connect more people to care.
Pietermaritzburg, KwaZulu-NatalAges 18 years+ - NCT06855810RecruitingPhase 2/Phase 3
New treatment study for children with T-cell ALL
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hefei, AnhuiAges 1 month–18 years - NCT06831526RecruitingEarly Phase 1
Chemoradiation with or without azeliragon for new glioblastoma
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
St Louis, MissouriAges 18 years+ - NCT06816927RecruitingPhase 2
Immunotherapy trial for glioblastoma with nivolumab and relatlimab
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
New York, New YorkAges 18 years+ - NCT01055093Recruiting
Study of diabetes complications in adults soon after diagnosis
This study follows adults who have been diagnosed with diabetes recently to better understand diabetes and its complications over time. It also includes a comparison group of people who do not have diabetes to help researchers see what changes are linked to diabetes.
Düsseldorf, North Rhine-WestphaliaAges 18–69 - NCT06805305RecruitingPhase 2
Immunotherapy for newly diagnosed glioblastoma
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
Gilbert, ArizonaAges 18 years+ - NCT06805773Recruiting
Educational videos for newly diagnosed sarcoma patients
This study tests whether watching short educational videos helps patients or caregivers of someone with advanced sarcoma that has spread. The trial focuses on people who haven't had any prior treatment for their sarcoma and are comfortable filling out questionnaires in English.
Toronto, OntarioAges 18 years+ - NCT06796998RecruitingPhase 2
Epcoritamab for newly diagnosed marginal zone lymphoma
This trial tests a new immunotherapy drug, epcoritamab, for people who have been recently diagnosed with marginal zone lymphoma (MZL) and haven't had treatment yet. The goal is to see if the drug can shrink tumors or control the disease.
Miami, FloridaAges 18 years+ - NCT06782542RecruitingPhase 2
A new drug combo for newly diagnosed AML with IDH1 mutation
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
Miami, FloridaAges 18–75 - NCT06773936Enrolling by invitationPhase 2
Adding asciminib to usual care for adults with newly diagnosed Ph+ ALL
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
Tucson, ArizonaAges 60 years+ - NCT06768489RecruitingPhase 1
Combination therapy for multiple myeloma and related conditions
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06764238RecruitingPhase 2/Phase 3
Treatment study for children with new B-cell ALL (intermediate/high risk)
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT06458257Recruiting
Stem cell transplant for high-risk AML with CEBPA mutation
This trial tests whether a stem cell transplant from a donor can help people with a specific type of acute myeloid leukemia (AML) that has a high risk of coming back. It is for patients who have the CEBPA gene mutation and other high-risk features.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06386302Recruiting
Chidamide, venetoclax, and azacitidine for new AML
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05994690RecruitingPhase 3
Newly diagnosed pediatric AML trial with extra treatment options
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
Utrecht, UtrechtAges 1 day–18 years - NCT06262438RecruitingPhase 2
Quizartinib plus chemo for children with FLT3-ITD AML
This study adds a targeted drug called quizartinib to standard chemotherapy for children with a certain type of acute myeloid leukemia (AML) that has a FLT3-ITD gene change. The goal is to see if this combination is safe and effective for treating newly diagnosed patients.
Utrecht, UtrechtAges 1 month–18 years - NCT06698887Recruiting
Long-term safety study of idecabtagene vicleucel for multiple myeloma in Korea
This study follows up on Korean adults with multiple myeloma who received the CAR T-cell therapy idecabtagene vicleucel (also called Ide-cel) in a previous trial (KarMMa-9) and did not have an optimal response after a stem cell transplant. The goal is to monitor long-term safety.
Hwasun, JeonranamdoAges 18 years+
Hear when a new Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for newly diagnosed?
- Yes. Clin2 currently lists 393 recruiting newly diagnosed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a newly diagnosed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a newly diagnosed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.